cytarabine has been researched along with diphenhydramine in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Baker, DK; McLeod, HL; Pui, CH; Rodman, JH | 1 |
| Belt, R; Coon, J; Cord, M; Dix, S; Geller, R; Howard, S | 1 |
| Assa'ad, A; Burns, K; Hershey, GK; Johnson, T; Lierl, MB; Metz, KA; Seidu, L | 1 |
1 review(s) available for cytarabine and diphenhydramine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
6 other study(ies) available for cytarabine and diphenhydramine
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Somnolence, hypotension, and metabolic acidosis following high-dose teniposide treatment in children with leukemia.
Topics: Acidosis; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Diphenhydramine; Drug Administration Schedule; Female; Humans; Hypotension; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Sleep Wake Disorders; Teniposide | 1991 |
Safety and efficacy of a continuous infusion, patient controlled anti-emetic pump to facilitate outpatient administration of high-dose chemotherapy.
Topics: Adult; Ambulatory Care; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carmustine; Cyclophosphamide; Cytarabine; Dexamethasone; Diphenhydramine; Etoposide; Evaluation Studies as Topic; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Infusion Pumps; Infusions, Intravenous; Lorazepam; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Nausea; Patient Acceptance of Health Care; Prospective Studies; Safety; Self Care; Thiotepa; Vomiting | 1999 |
Successful administration of cytarabine in a 16-month-old girl with acute myelogenous leukemia and cytarabine syndrome.
Topics: Cytarabine; Diphenhydramine; Drug Hypersensitivity; Female; Histamine Antagonists; Humans; Immunosuppressive Agents; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Methylprednisolone; Premedication; Ranitidine; Syndrome; Treatment Outcome | 2009 |